Efficacy of anti-IL-1 treatment in familial mediterranean fever: A systematic review of the literature

Biologics: Targets and Therapy

Volumn 10, Issue , 2016, Pages 75-80

  van der Hilst, Jeroen C H ^a,b   Moutschen, Michel ^c   Messiaen, Peter E ^a,b   Lauwerys, Bernard R ^d,e   Vanderschueren, Steven ^f  

^a JESSA HOSPITAL   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amyloidosis; Colchicines; Familial Mediterranean fever; Interleukin 1

Indexed keywords

CANAKINUMAB; COLCHICINE; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

ABSENCE OF SIDE EFFECTS; AMYLOIDOSIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; PROTEINURIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84962714526     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S102954     Document Type: Article

References (47)

1. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014;10:135-147
2. Gershoni-Baruch R, Brik R, Shinawi M, Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet. 2002;10:145-149
3. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33:273-282
4. Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum. 1991;21:143-155
5. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621-668
6. Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258-267
7. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al; Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416-2425
8. Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med. 2004;117: 208-210
9. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58:1516-1520
10. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70:2155-2158
11. Bodar EJ, van der Hilst JCH, Drenth JPH, van der Meer JWM, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med. 2005;63:260-264
12. Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469-484
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535
14. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40: 1879-1885
15. Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014;66:3241-3243
16. Gül A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243
17. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157:533-541
18. Hennig S, Bayegan K, Uffmann M, Thalhammer F, Winkler S. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra - case report and review. Rheumatol Int. 2012;32:1801-1804
19. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol. 2013;45:117-130
20. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci. 2006;103:9982-9987
21. Kuijk LM, Govers AMAP, Frenkel J, Hofhuis WJD. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007;66:1545-1546
22. Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest. 2007;37: 912-914
23. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med. 2008;66:489-491
24. Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24:676-678
25. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine. 2008;75:504-505
26. Alpay N, Sumnu A, Calışkan Y, Yazıcı H, Türkmen A, Gül A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2012;32:3277-3279
27. Petropoulou AD, Robin M, Socié G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation. 2010;90:102-103
28. Özen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38:516-518
29. Estublier C, Stankovic Stojanovic K, Bergerot J-F, Broussolle C, Sève P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine. 2013;80:645-649
30. Stankovic Stojanovic K, Delmas Y, Torres PU, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27:1898-1901
31. Celebi ZK, Kucuksahin O, Sengul S, Tuzuner A, Keven K. Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra. Clin Kidney J. 2014;7: 219-220
32. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167:695-696
33. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146:825-826
34. Mercan, R. Turan A, Bitik B, Tufan A, Haznedaroglu S, Goker B. Rapid resolution of protracted febrile myalgia syndrome with anakinra: Report of two cases. Mod Rheumatol. Epub 2014 Feb 18
35. Sevillano ÁM, Hernandez E, Gonzalez E, et al. Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. Nefrología. 2015;36(1): 63-66. Spanish.
36. Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015;9:1983-1987
37. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70:1347-1348
38. Eroglu FK, Beşbaş N, Topaloglu R, Ozen S. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015;35(10):1733-1737
39. Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35(2):441-446
40. Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation. 2015;38:27-31
41. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265-271
42. Dzhidoian Z, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Ann Rheum Dis. 2012;38:219-220
43. Buskila D, Zaks N, Neumann L, et al. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol. 1997;15:355-360
44. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-2371
45. van der Hilst JCH. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal. 2011;11:641-650
46. van der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med. 2005;5:87-98
47. Ben-Zvi I, Livneh A. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Isr Med Assoc J. 2014;16:271-273.